| Name | Wedgewood Manor |
|---|---|
| Location | 804 Main St W, Cavalier, North Dakota |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 40 |
| Occupancy Rate | 85.25% |
| Medicare ID (CCN) | 355087 |
| Legal Business Name | Pembina County Memorial Hospital Association |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1356487565 |
| Organization Name | PEMBINA COUNTY MEMORIAL HOSPITAL ASSOCIATION |
| Doing Business As | WEDGEWOOD MANOR |
| Address | 804 Main St W, Cavalier, ND 58220 |
| Phone Number | 701-265-8453 |
News Archive
Tensha Therapeutics announced today that it has raised $15 million in a Series A financing to advance the development of small molecule bromodomain inhibitors for the treatment of cancer and other conditions by regulating the transcription of disease-associated genes.
MedAptus(R), the market leader for charge capture technologies, today announced that Caritas Christi Health Care, also based in Boston, has implemented the company's Intelligent Charge Capture suite for revenue and compliance enhancement initiatives. The organization selected MedAptus' Practice Plus Edition on BlackBerry smartphone devices and web-enabled workstations for the capture of physician inpatient charges. In addition, Caritas Christi is rolling out the MedAptus Facility Edition for the capture of outpatient clinic charges, starting in the area of cardiology.
Cellectricon AB today announced that it has resumed its litigation against Fluxion Biosciences, Inc. Cellectricon filed the lawsuit in July 2009 in the United States District Court for the Northern District of California alleging infringement of several United States patents issued or licensed to Cellectricon for microfluidic technology used in Cellectricon's state-of-the-art ion channel drug screening solution, the Dynaflow(R)HT System. Cellectricon's U.S. Patents Nos. 7,390,650, 7,470,518 and 7,563,614 have been asserted in the litigation, as well as U.S. Patent No. 5,376,252, which is owned by Gyros, and licensed to Cellectricon.
Suit accused the medical device maker of giving doctors gifts in return for using its products. Elsewhere, a federal judge denied dismissal of a lawsuit against Novartis alleging a kickback campaign to boost its drugs covered by Medicare and Medicaid.
The Latino population is the nation's largest minority group at an estimated 47 million in 2008 and is predicted to make up 30% of the US population by 2050. At the same time, chronic diseases among Latinos are on the rise and require long-range strategies to prevent and clinically manage. Understanding the healthcare of this fastest growing population is critical to the healthcare debate and reform initiatives.
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Tensha Therapeutics announced today that it has raised $15 million in a Series A financing to advance the development of small molecule bromodomain inhibitors for the treatment of cancer and other conditions by regulating the transcription of disease-associated genes.
MedAptus(R), the market leader for charge capture technologies, today announced that Caritas Christi Health Care, also based in Boston, has implemented the company's Intelligent Charge Capture suite for revenue and compliance enhancement initiatives. The organization selected MedAptus' Practice Plus Edition on BlackBerry smartphone devices and web-enabled workstations for the capture of physician inpatient charges. In addition, Caritas Christi is rolling out the MedAptus Facility Edition for the capture of outpatient clinic charges, starting in the area of cardiology.
Cellectricon AB today announced that it has resumed its litigation against Fluxion Biosciences, Inc. Cellectricon filed the lawsuit in July 2009 in the United States District Court for the Northern District of California alleging infringement of several United States patents issued or licensed to Cellectricon for microfluidic technology used in Cellectricon's state-of-the-art ion channel drug screening solution, the Dynaflow(R)HT System. Cellectricon's U.S. Patents Nos. 7,390,650, 7,470,518 and 7,563,614 have been asserted in the litigation, as well as U.S. Patent No. 5,376,252, which is owned by Gyros, and licensed to Cellectricon.
Suit accused the medical device maker of giving doctors gifts in return for using its products. Elsewhere, a federal judge denied dismissal of a lawsuit against Novartis alleging a kickback campaign to boost its drugs covered by Medicare and Medicaid.
The Latino population is the nation's largest minority group at an estimated 47 million in 2008 and is predicted to make up 30% of the US population by 2050. At the same time, chronic diseases among Latinos are on the rise and require long-range strategies to prevent and clinically manage. Understanding the healthcare of this fastest growing population is critical to the healthcare debate and reform initiatives.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 23.33 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 7.34 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 62.82 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.89 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 8.77 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 6.92 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 30 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 95.24 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 8 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 34.22 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 36.8 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 8.14 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 0 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 88.46 | 82.93 |
News Archive
Tensha Therapeutics announced today that it has raised $15 million in a Series A financing to advance the development of small molecule bromodomain inhibitors for the treatment of cancer and other conditions by regulating the transcription of disease-associated genes.
MedAptus(R), the market leader for charge capture technologies, today announced that Caritas Christi Health Care, also based in Boston, has implemented the company's Intelligent Charge Capture suite for revenue and compliance enhancement initiatives. The organization selected MedAptus' Practice Plus Edition on BlackBerry smartphone devices and web-enabled workstations for the capture of physician inpatient charges. In addition, Caritas Christi is rolling out the MedAptus Facility Edition for the capture of outpatient clinic charges, starting in the area of cardiology.
Cellectricon AB today announced that it has resumed its litigation against Fluxion Biosciences, Inc. Cellectricon filed the lawsuit in July 2009 in the United States District Court for the Northern District of California alleging infringement of several United States patents issued or licensed to Cellectricon for microfluidic technology used in Cellectricon's state-of-the-art ion channel drug screening solution, the Dynaflow(R)HT System. Cellectricon's U.S. Patents Nos. 7,390,650, 7,470,518 and 7,563,614 have been asserted in the litigation, as well as U.S. Patent No. 5,376,252, which is owned by Gyros, and licensed to Cellectricon.
Suit accused the medical device maker of giving doctors gifts in return for using its products. Elsewhere, a federal judge denied dismissal of a lawsuit against Novartis alleging a kickback campaign to boost its drugs covered by Medicare and Medicaid.
The Latino population is the nation's largest minority group at an estimated 47 million in 2008 and is predicted to make up 30% of the US population by 2050. At the same time, chronic diseases among Latinos are on the rise and require long-range strategies to prevent and clinically manage. Understanding the healthcare of this fastest growing population is critical to the healthcare debate and reform initiatives.
› Verified 4 days ago